NanoCas for Extrahepatic Editing

About Mammoth Biosciences

Mammoth Biosciences, founded in 2017 and co-founded by CRISPR pioneer Jennifer Doudna, is a private biotech developing a next-generation CRISPR platform. The company's core innovation lies in discovering and engineering novel, ultracompact Cas enzymes (like its NanoCas systems) designed to overcome the delivery bottlenecks of in vivo gene editing, particularly for extrahepatic tissues. With a pipeline advancing towards the clinic, strategic partnerships, and a dual focus on therapeutics and diagnostics, Mammoth aims to unlock the full potential of genetic medicine.